For non-small-cell lung cancer (NSCLC) patients undergoing immunotherapy blocking the PD-1/PD-L1 interaction, the cancer cell PD-L1 expression level is a determinant of treatment efficiency. This evidence concerns the gene CD274 and non-small cell lung carcinoma.